Table 2

 Clinical outcome of patients treated with sirolimus

Case NoSnellen visual acuity pretreatmentSnellen visual acuity post-treatmentIntraocular inflammation BIO score RE/LE pretreatmentIntraocular inflammation BIO score RE/LE post-treatmentPretreatment prednisolone dose/current prednisolone doseClinical outcome
BIO, binocular indirect score; CMO, cystoid macular oedema; HM, hand movements; IV MP, intravenous methylprednisolone.
16/6, 6/96/5+3, 6/6+30 11 240 mg/10 mgTreatment failure
Initial control of inflammation followed by relapse on tapering treatment requiring higher doses of sirolimus with intolerable side effects
Current medication: tacrolimus, prednisolone and sirolimus
26/18, 6/126/9, 6/93 30 040 mg/6 mgSymptom improvement: reduction of floaters
36/36, 6/46/36, 6/41 00 0Intermittent IV MP/0 mgSymptom improvement: reduction in pain and photophobia
46/6+1, 6/126/5−1, 6/91 10 030 mg/0 mgReduction in vasculitis and regression of neovascularisation
51/60, 6/181/60, 6/91 20 040 mg/15 mgTreatment failure
Despite reduction of inflammation mild CMO persists. Treatment withdrawn due to side effects
Current medication: tacrolimus and oral corticosteroids
66/5, 6/96/5, 6/50 20 050 mg reducing to 20 mg/0 mgSymptom improvement: reduction in pain
Regression of vasculitis with no further flare ups
76/18, HM6/18, HM0 00 015 mg/7.5 mgMarked improvement in systemic symptoms of Behçet’s syndrome
Regression of vasculitis with no further flare ups
8HM, 6/12HM, 6/122 21 1Intermittent IV MP/6 mg and pulsed IV MPTreatment failure
Continuing episodes of vasculitis leading to transient vision loss requiring repeated IV MP
Currently on tacrolimus, prednisolone, and sirolimus